FindTrial
Sign In

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of OVF in Patients With Cancer and Breakthrough Pain

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of OVF in Patients With Cancer and Breakthrough Pain

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220446
Enrollment
Unknown
Registered
2007-09-20
Start date
2007-09-20
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer pain (breakthrough pain)

Interventions

investigational material(s) Generic name etc : OVF INN of investigational material : fentanyl Therapeutic category code : 821 Synthetic narcotics Dosage and Administration for Investigational material

Sponsors

Taiho Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)20 years or older at the time of informed consent 2)Patients who are possible to be hospitalized 3)Patients who have average of 1 to 4 episodes/day of breakthrough pain controlled by a rescue medication

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Pain Intensity Difference, Pain Relief and safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026